Trial Outcomes & Findings for A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis (NCT NCT03178487)
NCT ID: NCT03178487
Last Updated: 2023-03-07
Results Overview
ASAS 40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
COMPLETED
PHASE2
187 participants
Baseline and Week 14
2023-03-07
Participant Flow
Participants were enrolled between October 24, 2017, and September 10, 2018 at 62 sites in 20 countries in North America, Eastern and Western Europe, Asia, and Oceania. This study consists of a 14-week double-blind treatment period (Period 1) and a 90-week long-term extension period (Period 2) for participants who completed Period 1.
Eligible participants were randomized in a 1:1 ratio to one of two treatment groups. Randomization was stratified by screening concentrations of high-sensitivity C-reactive protein (hsCRP; ≤ upper limit of normal \[ULN\] vs \> ULN; where the ULN is 2.87 mg/L) and geographical region (USA and Canada, Japan, rest of the world).
Participant milestones
| Measure |
Placebo / Upadacitinib 15 mg
Participants received matching placebo orally once a day for 14 weeks in Period 1. Participants then received upadacitinib 15 mg orally once a day for 90 weeks in Period 2.
|
Upadacitinib 15 mg
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1, and continued to receive upadacitinib 15 mg orally once a day for 90 weeks in Period 2.
|
|---|---|---|
|
Period 1
STARTED
|
94
|
93
|
|
Period 1
Received Treatment
|
94
|
93
|
|
Period 1
COMPLETED
|
90
|
89
|
|
Period 1
NOT COMPLETED
|
4
|
4
|
|
Period 2
STARTED
|
90
|
89
|
|
Period 2
Received Treatment
|
89
|
89
|
|
Period 2
COMPLETED
|
69
|
70
|
|
Period 2
NOT COMPLETED
|
21
|
19
|
Reasons for withdrawal
| Measure |
Placebo / Upadacitinib 15 mg
Participants received matching placebo orally once a day for 14 weeks in Period 1. Participants then received upadacitinib 15 mg orally once a day for 90 weeks in Period 2.
|
Upadacitinib 15 mg
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1, and continued to receive upadacitinib 15 mg orally once a day for 90 weeks in Period 2.
|
|---|---|---|
|
Period 1
Adverse Event
|
1
|
2
|
|
Period 1
Withdrawal by Subject
|
2
|
1
|
|
Period 1
Lost to Follow-up
|
1
|
0
|
|
Period 1
Other
|
0
|
1
|
|
Period 2
Adverse Event
|
4
|
4
|
|
Period 2
Withdrawal by Subject
|
6
|
6
|
|
Period 2
Lost to Follow-up
|
2
|
2
|
|
Period 2
Coronavirus Disease 2019 (COVID-19) Logistical Restrictions
|
1
|
0
|
|
Period 2
Other
|
8
|
7
|
Baseline Characteristics
Participants with available data
Baseline characteristics by cohort
| Measure |
Placebo
n=94 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=93 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
Total
n=187 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Sex: Female, Male
Male
|
69 Participants
n=94 Participants
|
63 Participants
n=93 Participants
|
132 Participants
n=187 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
5 Participants
n=94 Participants
|
4 Participants
n=93 Participants
|
9 Participants
n=187 Participants
|
|
Age, Continuous
|
43.7 years
STANDARD_DEVIATION 12.07 • n=94 Participants
|
47.0 years
STANDARD_DEVIATION 12.78 • n=93 Participants
|
45.4 years
STANDARD_DEVIATION 12.50 • n=187 Participants
|
|
Age, Customized
< 40 years
|
39 Participants
n=94 Participants
|
28 Participants
n=93 Participants
|
67 Participants
n=187 Participants
|
|
Age, Customized
40 - 64 years
|
53 Participants
n=94 Participants
|
56 Participants
n=93 Participants
|
109 Participants
n=187 Participants
|
|
Age, Customized
≥ 65 years
|
2 Participants
n=94 Participants
|
9 Participants
n=93 Participants
|
11 Participants
n=187 Participants
|
|
Sex: Female, Male
Female
|
25 Participants
n=94 Participants
|
30 Participants
n=93 Participants
|
55 Participants
n=187 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
89 Participants
n=94 Participants
|
89 Participants
n=93 Participants
|
178 Participants
n=187 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=94 Participants
|
0 Participants
n=93 Participants
|
0 Participants
n=187 Participants
|
|
Race/Ethnicity, Customized
White
|
76 Participants
n=94 Participants
|
79 Participants
n=93 Participants
|
155 Participants
n=187 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
2 Participants
n=94 Participants
|
1 Participants
n=93 Participants
|
3 Participants
n=187 Participants
|
|
Race/Ethnicity, Customized
Asian
|
16 Participants
n=94 Participants
|
13 Participants
n=93 Participants
|
29 Participants
n=187 Participants
|
|
Region
USA and Canada
|
10 Participants
n=94 Participants
|
9 Participants
n=93 Participants
|
19 Participants
n=187 Participants
|
|
Region
Western Europe
|
33 Participants
n=94 Participants
|
30 Participants
n=93 Participants
|
63 Participants
n=187 Participants
|
|
Region
Eastern Europe
|
34 Participants
n=94 Participants
|
36 Participants
n=93 Participants
|
70 Participants
n=187 Participants
|
|
Region
Japan
|
7 Participants
n=94 Participants
|
6 Participants
n=93 Participants
|
13 Participants
n=187 Participants
|
|
Region
South Korea
|
7 Participants
n=94 Participants
|
6 Participants
n=93 Participants
|
13 Participants
n=187 Participants
|
|
Region
Australia and New Zealand
|
3 Participants
n=94 Participants
|
6 Participants
n=93 Participants
|
9 Participants
n=187 Participants
|
|
Duration Since Ankylosing Spondylitis (AS) Diagnosis
|
6.0 years
STANDARD_DEVIATION 6.79 • n=94 Participants
|
7.8 years
STANDARD_DEVIATION 10.64 • n=93 Participants
|
6.9 years
STANDARD_DEVIATION 8.94 • n=187 Participants
|
|
Duration of Ankylosing Spondylitis Symptoms
|
14.0 years
STANDARD_DEVIATION 9.86 • n=94 Participants
|
14.8 years
STANDARD_DEVIATION 11.64 • n=93 Participants
|
14.4 years
STANDARD_DEVIATION 10.76 • n=187 Participants
|
|
Patient's Global Assessment of Disease Activity (PtGA)
|
6.8 units on a scale
STANDARD_DEVIATION 1.66 • n=94 Participants • Participants with available data
|
6.6 units on a scale
STANDARD_DEVIATION 1.81 • n=91 Participants • Participants with available data
|
6.7 units on a scale
STANDARD_DEVIATION 1.73 • n=185 Participants • Participants with available data
|
|
Patient's Assessment of Total Back Pain
|
6.7 units on a scale
STANDARD_DEVIATION 1.78 • n=94 Participants • Participants with available data
|
6.8 units on a scale
STANDARD_DEVIATION 1.77 • n=92 Participants • Participants with available data
|
6.8 units on a scale
STANDARD_DEVIATION 1.78 • n=186 Participants • Participants with available data
|
|
Bath Ankylosing Spondylitis Functional Index
|
5.5 units on a scale
STANDARD_DEVIATION 2.17 • n=94 Participants • Participants with available data
|
5.4 units on a scale
STANDARD_DEVIATION 2.36 • n=91 Participants • Participants with available data
|
5.4 units on a scale
STANDARD_DEVIATION 2.26 • n=185 Participants • Participants with available data
|
|
Inflammation
|
6.7 units on a scale
STANDARD_DEVIATION 1.90 • n=94 Participants • Participants with available data
|
6.5 units on a scale
STANDARD_DEVIATION 1.99 • n=92 Participants • Participants with available data
|
6.6 units on a scale
STANDARD_DEVIATION 1.94 • n=186 Participants • Participants with available data
|
|
High-sensitivity C-reactive Protein (hsCRP) Level at Screening
> upper limit of normal
|
68 Participants
n=94 Participants
|
67 Participants
n=93 Participants
|
135 Participants
n=187 Participants
|
|
High-sensitivity C-reactive Protein (hsCRP) Level at Screening
≤ upper limit of normal
|
26 Participants
n=94 Participants
|
26 Participants
n=93 Participants
|
52 Participants
n=187 Participants
|
PRIMARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set; participants who discontinued study drug prior to Week 14 or with missing data at Week 14 were counted as non-responders (non-responder imputation).
ASAS 40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Outcome measures
| Measure |
Placebo
n=94 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=93 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14
|
25.5 percentage of participants
Interval 16.7 to 34.3
|
51.6 percentage of participants
Interval 41.5 to 61.8
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with longitudinal data from observed cases up to Week 14 was used.
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.
Outcome measures
| Measure |
Placebo
n=84 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=84 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14
|
-0.54 score on a scale
Interval -0.71 to -0.37
|
-1.45 score on a scale
Interval -1.62 to -1.28
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set; the following MRI data were included in the analysis: Baseline includes MRI data up to 3 days post first dose of study drug and Week 14 includes MRI data up to first dose of period 2 study drug.
In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108.
Outcome measures
| Measure |
Placebo
n=60 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=68 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for the Spine at Week 14
|
-0.22 score on a scale
Interval -2.01 to 1.57
|
-6.93 score on a scale
Interval -8.58 to -5.28
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set; non-responder imputation
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.
Outcome measures
| Measure |
Placebo
n=94 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=93 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14
|
23.4 percentage of participants
Interval 14.8 to 32.0
|
45.2 percentage of participants
Interval 35.0 to 55.3
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with longitudinal data from observed cases up to Week 14 was used.
The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.
Outcome measures
| Measure |
Placebo
n=88 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=88 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score
|
-2.67 score on a scale
Interval -3.58 to -1.75
|
-4.20 score on a scale
Interval -5.12 to -3.29
|
SECONDARY outcome
Timeframe: Week 14Population: Full analysis set; non-responder imputation
ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Outcome measures
| Measure |
Placebo
n=94 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=93 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) Partial Remission
|
1.1 percentage of participants
Interval 0.0 to 3.1
|
19.4 percentage of participants
Interval 11.3 to 27.4
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with longitudinal data from observed cases up to Week 14 was used.
The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.
Outcome measures
| Measure |
Placebo
n=86 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=86 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14
|
-1.30 score on a scale
Interval -1.74 to -0.86
|
-2.29 score on a scale
Interval -2.73 to -1.85
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set participants with available data
The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.
Outcome measures
| Measure |
Placebo
n=89 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=89 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14
|
-0.14 score on a scale
Interval -0.29 to 0.01
|
-0.37 score on a scale
Interval -0.52 to -0.21
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set participants with Baseline enthesitis; a mixed effect model repeat measurement (MMRM) analysis with longitudinal data from observed cases up to Week 14 was used.
The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses.
Outcome measures
| Measure |
Placebo
n=51 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=50 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14
|
-1.41 score on a scale
Interval -2.02 to -0.8
|
-2.25 score on a scale
Interval -2.86 to -1.64
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis participants who were employed and with available data
The Work Productivity and Activity Impairment Questionnaire: Axial Spondyloarthritis, Version 2.0 (WPAI-Axial Spondyloarthritis) measures the effect of overall health and specific symptoms on productivity at work and outside of work. It consists of 6 questions. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity. Overall Work Impairment indicates the percentage of overall work impairment due to health problems. A negative change from Baseline indicates improvement.
Outcome measures
| Measure |
Placebo
n=53 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=55 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment at Week 14
|
-12.60 percent impairment
Interval -19.04 to -6.15
|
-18.11 percent impairment
Interval -24.73 to -11.5
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set participants with available data; a mixed effect model repeat measurement (MMRM) analysis with longitudinal data from observed cases up to Week 14 was used.
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.
Outcome measures
| Measure |
Placebo
n=88 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=88 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in ASAS Health Index (HI) at Week 14
|
-1.38 score on a scale
Interval -2.11 to -0.65
|
-2.75 score on a scale
Interval -3.48 to -2.02
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set; non-responder imputation
ASAS 20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Outcome measures
| Measure |
Placebo
n=94 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=93 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Percentage of Participants Achieving an ASAS 20 Response at Week 14
|
40.4 percentage of participants
Interval 30.5 to 50.3
|
64.5 percentage of participants
Interval 54.8 to 74.2
|
SECONDARY outcome
Timeframe: Baseline and Week 14Population: Full analysis set; the following MRI data were included in the analysis: Baseline includes MRI data up to 3 days post first dose of study drug and Week 14 includes MRI data up to first dose of period 2 study drug.
In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum score for all SI joints across 6 slices is 72.
Outcome measures
| Measure |
Placebo
n=59 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=68 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in SPARCC MRI Score for Sacroiliac Joints at Week 14
|
-0.22 score on a scale
Interval -1.47 to 1.04
|
-3.91 score on a scale
Interval -5.05 to -2.77
|
POST_HOC outcome
Timeframe: Baseline and Week 14Population: Full analysis set; the analysis includes all participants with available MRI data collected at Baseline and Week 14
In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six DVUs representing the 6 most abnormal DVUs were selected to calculate the SPARCC MRI spine score. For each DVU, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least 1 quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A supplemental post-hoc SPARCC MRI analysis included all MRI data collected at nominal visits at Baseline and Week 14.
Outcome measures
| Measure |
Placebo
n=88 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=89 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in SPARCC MRI Score for the Spine at Week 14 - Supplementary Analysis
|
-0.65 score on a scale
Interval -2.2 to 0.9
|
-6.86 score on a scale
Interval -8.41 to -5.3
|
POST_HOC outcome
Timeframe: Baseline and Week 14Population: Full analysis set; the analysis includes all participants with available MRI data collected at Baseline and Week 14
In the SPARCC MRI assessment of the sacroiliac joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum score for all SI joints across 6 slices is 72. A supplemental post-hoc SPARCC MRI analysis was done to include all MRI data collected at nominal visits at Baseline and Week 14.
Outcome measures
| Measure |
Placebo
n=87 Participants
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Upadacitinib 15 mg
n=89 Participants
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
|---|---|---|
|
Change From Baseline in SPARCC MRI Score for Sacroiliac Joints at Week 14 - Supplementary Analysis
|
-0.90 score on a scale
Interval -2.01 to 0.2
|
-3.45 score on a scale
Interval -4.54 to -2.36
|
Adverse Events
Period 1: Placebo
Period 1: Upadacitinib 15 mg
Period 1 + 2: Upadacitinib 15 mg
Serious adverse events
| Measure |
Period 1: Placebo
n=94 participants at risk
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Period 1: Upadacitinib 15 mg
n=93 participants at risk
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
Period 1 + 2: Upadacitinib 15 mg
n=182 participants at risk
Participants originally assigned to placebo received upadacitinib 15 mg from Week 14 to Week 104. Participants originally assigned to upadacitinib received upadacitinib 15 mg from Week 0 to Week 104.
|
|---|---|---|---|
|
Cardiac disorders
CARDIOVASCULAR DISORDER
|
1.1%
1/94 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/182 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Ear and labyrinth disorders
VERTIGO POSITIONAL
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Gastrointestinal disorders
APPENDICITIS NONINFECTIVE
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Gastrointestinal disorders
COLITIS
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Injury, poisoning and procedural complications
ANKLE FRACTURE
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Injury, poisoning and procedural complications
FACIAL BONES FRACTURE
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Injury, poisoning and procedural complications
MULTIPLE FRACTURES
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Injury, poisoning and procedural complications
RADIUS FRACTURE
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE INCREASED
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Musculoskeletal and connective tissue disorders
OSTEOARTHRITIS
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Musculoskeletal and connective tissue disorders
PERIARTHRITIS
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Musculoskeletal and connective tissue disorders
SPINAL OSTEOARTHRITIS
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
1.1%
1/93 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF THE TONGUE
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Nervous system disorders
HEMIPARAESTHESIA
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Nervous system disorders
SYNCOPE
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Reproductive system and breast disorders
BENIGN PROSTATIC HYPERPLASIA
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Reproductive system and breast disorders
UTERINE PROLAPSE
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Skin and subcutaneous tissue disorders
BLISTER
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Vascular disorders
AORTIC DILATATION
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Vascular disorders
HYPERTENSION
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Vascular disorders
HYPERTENSIVE EMERGENCY
|
0.00%
0/94 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.55%
1/182 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
Other adverse events
| Measure |
Period 1: Placebo
n=94 participants at risk
Participants received matching placebo orally once a day for 14 weeks in Period 1.
|
Period 1: Upadacitinib 15 mg
n=93 participants at risk
Participants received 15 mg upadacitinib orally once a day for 14 weeks in Period 1.
|
Period 1 + 2: Upadacitinib 15 mg
n=182 participants at risk
Participants originally assigned to placebo received upadacitinib 15 mg from Week 14 to Week 104. Participants originally assigned to upadacitinib received upadacitinib 15 mg from Week 0 to Week 104.
|
|---|---|---|---|
|
Gastrointestinal disorders
DIARRHOEA
|
5.3%
5/94 • Number of events 5 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
5.4%
5/93 • Number of events 5 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
7.1%
13/182 • Number of events 14 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Gastrointestinal disorders
NAUSEA
|
5.3%
5/94 • Number of events 5 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
1.1%
1/93 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
3.3%
6/182 • Number of events 6 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Infections and infestations
NASOPHARYNGITIS
|
4.3%
4/94 • Number of events 4 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
5.4%
5/93 • Number of events 6 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
19.2%
35/182 • Number of events 48 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
|
3.2%
3/94 • Number of events 3 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
2.2%
2/93 • Number of events 2 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
12.6%
23/182 • Number of events 30 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Investigations
ALANINE AMINOTRANSFERASE INCREASED
|
2.1%
2/94 • Number of events 2 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
5.4%
5/93 • Number of events 5 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
7.1%
13/182 • Number of events 14 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE INCREASED
|
2.1%
2/94 • Number of events 2 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
8.6%
8/93 • Number of events 8 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
15.9%
29/182 • Number of events 35 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Musculoskeletal and connective tissue disorders
ANKYLOSING SPONDYLITIS
|
4.3%
4/94 • Number of events 4 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
0.00%
0/93 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
7.1%
13/182 • Number of events 20 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
4.3%
4/94 • Number of events 5 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
1.1%
1/93 • Number of events 1 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
6.0%
11/182 • Number of events 11 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
|
Nervous system disorders
HEADACHE
|
2.1%
2/94 • Number of events 2 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
5.4%
5/93 • Number of events 5 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
8.2%
15/182 • Number of events 16 • Period 1: From the first dose of study drug up to Week 14 or up to 30 days after last dose for participants who discontinued study drug prior to Week 14. Period 1+2: From Week 14 to 30 days after last dose (up to 94 weeks) for participants initially assigned to placebo; From Week 1 up to 30 days after last dose (up to 108 weeks) for participants initially assigned to upadacitinib.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
- Publication restrictions are in place
Restriction type: OTHER